Shasun Pharmaceuticals receives USFDA approval for Carisoprodol Tablets

16 Nov 2015 Evaluate

Shasun Pharmaceuticals has received an approval from the United States Food & Drug Administration (USFDA) for Carisoprodol Tablets USP 250 mg and 350 mg. The product will be manufactured at the Pondicherry facility of the company and will be distributed in US through a partner. The product is expected to be launched shortly.

Carisoprodol Tablets 250 mg & 350 mg has sales of approximately $38 million. While the 350 mg has few Generic players, Shasun expects to be the first marketed generic player in the $16 million Carisoprodol Tablets 250 mg opportunity.

Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.


Peers
Company Name CMP
Sun Pharma Inds. 1534.00
Dr. Reddys Lab 6041.95
Cipla 1381.55
Zydus Lifesciences 949.70
Lupin 1614.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.